Wilex’s subsidiary, Heidelberg Pharma, is developing antibody-targeted amanitin conjugates (ATACs), which are differentiated from first-in-class, and developing antibody drug conjugates by potential efficacy against dormant and proliferating tumours. The investment case rests on the new partnerships for the ATAC pipeline and on clinical partnering progress for renal cancer programmes. Our DCF valuation is €41m.
